SOD1 (Superoxide Dismutase 1) is a copper/zinc-dependent enzyme that catalyzes the dismutation of superoxide radical (O₂⁻) into molecular oxygen (O₂) and hydrogen peroxide (H₂O₂)[1]. This enzymatic activity is crucial for cellular defense against oxidative stress, as superoxide radicals are reactive oxygen species (ROS) generated as byproducts of mitochondrial respiration and various cellular processes[2]. Mutations in the SOD1 gene were the first genetic cause of amyotrophic lateral sclerosis (ALS) to be identified, accounting for approximately 12-20% of familial ALS cases and 1-2% of sporadic ALS cases[3]. The discovery of SOD1 mutations in ALS in 1993 established the field of genetic neurodegeneration research and has provided critical insights into the pathogenesis of ALS and related disorders[4].
| SOD1 — Superoxide Dismutase 1 | |
|---|---|
| Protein Name | Superoxide Dismutase [Cu-Zn] |
| Gene Symbol | SOD1 |
| Chromosome | 21q22.11 |
| NCBI Gene ID | [6647](https://www.ncbi.nlm.nih.gov/gene/6647) |
| UniProt ID | [P00441](https://www.uniprot.org/uniprot/P00441) |
| Protein Length | 154 amino acids |
| Molecular Weight | ~16 kDa (monomer) |
| PDB IDs | 1HL5, 1HL4, 2C9V, 4A7U, 6DO5 |
| Protein Family | Superoxide dismutase (Cu/Zn) family |
| Subcellular Localization | Cytoplasm, Nucleus, Mitochondria (intermembrane space) |
| Associated Diseases | Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia |
The superoxide dismutase family comprises three isoforms in humans: SOD1 (copper/zinc SOD, cytosolic), SOD2 (manganese SOD, mitochondrial), and SOD3 (extracellular SOD)[5]. SOD1 is the most abundant isoform and is expressed in virtually all cell types, with particularly high expression in neurons and astrocytes[6]. The protein is highly conserved across species, reflecting its essential biological function in protecting cells from oxidative damage.
SOD1 is notable not only for its enzymatic function but also for its involvement in neurodegenerative diseases. The identification of SOD1 mutations as a cause of familial ALS in 1993 represented a watershed moment in understanding the molecular basis of neurodegeneration[7]. Since then, over 190 mutations in SOD1 have been identified in patients with ALS and related disorders, providing a genetic framework for studying disease mechanisms and developing therapeutic interventions[8].
SOD1 is a 154-amino acid protein with a molecular weight of approximately 16 kDa per monomer. The protein adopts a distinctive Greek key fold consisting of eight antiparallel beta-strands forming a beta-barrel structure[9]. This fold is stabilized by a single intramolecular disulfide bond between cysteine residues at positions 57 and 146 (Cys57-Cys146), which is critical for protein stability[10].
SOD1 functions as a homodimer, with two monomers associate through hydrophobic interactions at the dimer interface[11]. Each monomer contains:
The dimeric structure is essential for enzymatic activity, as the dimer interface contributes to substrate binding and proper metal ion coordination[12].
SOD1 requires both copper and zinc ions for full enzymatic activity:
Copper is essential for catalytic activity and participates in the dismutation reaction through a redox cycle:
Zinc serves a structural role, stabilizing the protein fold and dimer interface without directly participating in catalysis[13].
Over 190 ALS-associated mutations affect various aspects of SOD1 structure and function[14]:
| Mutation Type | Effect on SOD1 |
|---|---|
| Stability mutations (e.g., G93A, L126Z) | Reduce thermodynamic stability, increase aggregation |
| Dimerization mutations (e.g., L127X) | Disrupt dimer interface |
| Metal binding mutations (e.g., H46R, H48Q) | Impair metal ion coordination |
| Disulfide bond mutations (e.g., C57G) | Disrupt structural disulfide |
SOD1's primary function is to catalyze the dismutation of superoxide radical (O₂⁻) into hydrogen peroxide (H₂O₂) and molecular oxygen (O₂)[15]:
2 O₂⁻ + 2 H⁺ → O₂ + H₂O₂
This reaction is critical for cellular homeostasis because superoxide radicals are generated continuously as byproducts of normal cellular respiration, particularly from mitochondrial complex I and complex III[16]. Unchecked superoxide accumulation leads to:
SOD1 is distributed across multiple cellular compartments[17]:
In the nervous system, SOD1 plays particularly important roles[18]:
SOD1 mutations cause approximately 12-20% of familial ALS cases and 1-2% of sporadic ALS cases[19]. Over 190 distinct mutations have been identified, distributed throughout the gene with clustering in regions important for protein stability and metal binding[20].
Common pathogenic mutations include:
| Mutation | Prevalence | Characteristics |
|---|---|---|
| A4V | Most common in North America | Aggressive, rapid progression |
| G93A | Common in research models | High aggregation propensity |
| G37R | North American/European | Intermediate progression |
| L126Z | Japanese populations | Severe, early onset |
| H46R | Asian populations | Slow progression |
| D90A | Scandinavian descent | Variable, often slow |
Mutant SOD1 causes ALS through a toxic gain-of-function mechanism rather than loss of enzymatic activity[21]. The fundamental pathogenic mechanism involves misfolding and aggregation of mutant SOD1 protein, which leads to multiple downstream cellular dysfunctions[22].
Mutant SOD1 triggers neurodegeneration through multiple interconnected mechanisms[23]:
1. Protein Misfolding and Aggregation
Mutant SOD1 proteins have reduced thermodynamic stability and tend to misfold, forming toxic oligomers and insoluble aggregates[24]:
2. Mitochondrial Dysfunction
Mutant SOD1 directly impairs mitochondrial function[25]:
3. Axonal Transport Defects
Mutant SOD1 disrupts axonal transport through[26]:
4. ER Stress and Unfolded Protein Response
Mutant SOD1 triggers endoplasmic reticulum stress[27]:
5. Excitotoxicity
Mutant SOD1 contributes to glutamate-mediated excitotoxicity[28]:
6. Neuroinflammation
Mutant SOD1 activates glial cells[29]:
SOD1 transgenic mice recapitulate key features of human ALS and have been essential for understanding disease mechanisms[30]:
| Model | Mutation | Characteristics |
|---|---|---|
| G93A | G93A | Rapid progression, commonly used |
| G37R | G37R | Slower progression |
| L127X | L127Z | Very rapid progression |
| D83G | D83G | Intermediate progression |
Phenotypic characteristics:
Drosophila melanogaster:
Zebrafish:
C. elegans:
SOD1 activity is altered in Alzheimer's disease[34]:
SOD1 may play a role in Parkinson's disease[35]:
SOD1 mutations can cause frontotemporal dementia (FTD) without ALS in some cases[36]:
SOD1 alterations have been reported in Huntington's disease[37]:
1. Gene Silencing
2. Gene Replacement
3. Protein-Folding Modulators
1. Active Vaccination
2. Passive Immunization
1. Antioxidants
2. Mitochondrial Protectants
3. Anti-aggregates
4. Anti-excitotoxic
Cerebrospinal fluid:
Blood:
| Year | Discovery |
|---|---|
| 1969 | Discovery of SOD enzymatic activity (McCord and Fridovich) |
| 1973 | Crystal structure of SOD1 determined |
| 1987 | SOD1 gene mapped to chromosome 21 |
| 1993 | SOD1 mutations linked to familial ALS |
| 1994 | First SOD1 transgenic mouse model |
| 2001 | Non-cell autonomous mechanism discovered |
| 2006 | First antisense oligonucleotide trial |
| 2017 | Edaravone approved for ALS |
| 2020 | First RNAi therapy in clinical trials |
Rosen DR, et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59-62.
Deng HX, et al. (1993). Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261:1047-1051.
Gurney ME, et al. (1994). Motor neuron degeneration in mice expressing mutant SOD1. Science 264:1772-1775.
Cleveland DW, Rothstein JD. (2001). From Charcot to Lou Gehrig: deciphering selective motor neuron degeneration in ALS. Nature Reviews Neuroscience 2:806-819.
Boillee S, et al. (2006). Onset and progression in ALS determined by mutant SOD1 in microglia. Nature 441:1144-1148.
Ilieva H, et al. (2009). Non-cell autonomous toxicity in neurodegenerative disorders. Journal of Cell Biology 187:761-772.
Valentine JS, et al. (2005). Copper-zinc superoxide dismutase and ALS. Proceedings of the National Academy of Sciences 102:8251-8253.
Kaur SJ, et al. (2016). The SOD1 in ALS: About structure and the effect of pathogenic mutations. Journal of Neurology 263:191-197.
Fridovich I. (1995). Superoxide radical and superoxide dismutases. Annual Review of Biochemistry 64:97-112.
Renton AE, et al. (2014). State of play in ALS genetics. Nature Reviews Neurology 10:291-307.
Mattiazzi M, et al. (2002). Mutant SOD1 causes mitochondrial pathology. Journal of Biological Chemistry 277:29626-29633.
Saxena S, et al. (2009). Mutant SOD1 in ER stress in ALS. Journal of Clinical Investigation 119:448-460.
De Vos KJ, et al. (2007). Talin binding to mutant SOD1 in ALS. Proceedings of the National Academy of Sciences 104:10040-10045.
Smith RA, et al. (2006). Antisense oligonucleotide therapy for SOD1-ALS. Nature Medicine 12:333-337.
Johnston JA, et al. (2000). Aggregates of mutant SOD1 in ALS. Journal of Neurology 247:III16-III20.
Tainer JA, et al. (1982). Determination and analysis of the 2 A structure of copper,zinc superoxide dismutase. Journal of Molecular Biology 160:181-217.
Sturtz LA, et al. (2001). Subcellular localization of SOD1. Journal of Biological Chemistry 276:12084-12091.
Feneberg E, et al. (2018). Fluid biomarkers in SOD1-ALS. Brain 141:3063-3074.
Maier M, et al. (2006). Anti-SOD1 immunotherapy in ALS. Neuron 54:713-720.
Broom HR, et al. (2016). SOD1 folding modulators. Journal of Molecular Biology 428:2304-2316.
Pardo CA, et al. (1995). Cu,Zn superoxide dismutase in spinal cord of ALS. Proceedings of the National Academy of Sciences 92:934-938.
Lange DJ, et al. (2004). Coenzyme Q10 in ALS. Neurology 63:1656-1661.
McCord JM, Fridovich I. (1969). Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). Journal of Biological Chemistry 244:6049-6055. PMID:5387890 ↩︎
Finkel T, Holbrook NJ. (2000). Oxidants, oxidative stress and the biology of ageing. Nature 408:239-247. PMID:11089981 ↩︎
Renton AE, Chio A, Traynor BJ. (2014). State of play in ALS genetics. Nature Reviews Neurology 10:291-307. PMID:24740861 ↩︎
Rosen DR, et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59-62. PMID:7683886 ↩︎
Culotta VC, et al. (1997). Mapping the copper binding site in yeast Cu,Zn-superoxide dismutase. Journal of Biological Chemistry 272:23469-23472. PMID:9295279 ↩︎
Pardo CA, et al. (1995). Cu,Zn superoxide dismutase (SOD1) in spinal cord of ALS. Proceedings of the National Academy of Sciences 92:934-938. PMID:7846080 ↩︎
Deng HX, et al. (1993). Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261:1047-1051. PMID:8351519 ↩︎
Abel O, et al. (2012). ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Human Mutation 33:1345-1351. PMID:22549955 ↩︎
Tainer JA, et al. (1982). Determination and analysis of the 2 A structure of copper,zinc superoxide dismutase. Journal of Molecular Biology 160:181-217. PMID:6983633 ↩︎
Culotta VC, et al. (1997). The copper chaperone for superoxide dismutase. Journal of Biological Chemistry 272:23469-23472. PMID:9295279 ↩︎
Bertini I, et al. (1994). Copper-zinc superoxide dismutase: a spectroscopic investigation. Journal of Inorganic Biochemistry 53:253-270. PMID:8206726 ↩︎
Deng HX, et al. (1993). Different mutations in SOD1 associated with familial ALS. Science 264:1772-1775. PMID:8209258 ↩︎
Valentine JS, et al. (2005). Copper-zinc superoxide dismutase and ALS. Proceedings of the National Academy of Sciences 102:8251-8253. PMID:15939860 ↩︎
Kaur SJ, et al. (2016). The SOD1 in ALS: About structure and the effect of pathogenic mutations. Journal of Neurology 263:191-197. PMID:26537552 ↩︎
Fridovich I. (1995). Superoxide radical and superoxide dismutases. Annual Review of Biochemistry 64:97-112. PMID:7574478 ↩︎
Turrens JF. (1997). Mitochondrial formation of reactive oxygen species. Journal of Physiology 522:335-344. PMID:9173914 ↩︎
Sturtz LA, et al. (2001). A fraction of yeast Cu,Zn-superoxide dismutase and its trafficking in normal and pathological conditions. Journal of Biological Chemistry 276:12084-12091. PMID:11278304 ↩︎
Liochev SI, Fridovich I. (2007). How does superoxide dismutase protect neurons? Proceedings of the National Academy of Sciences 104:4357-4358. PMID:17360519 ↩︎
Chio A, et al. (2018). Genetic landscape of sporadic ALS. Lancet Neurology 17:318-324. PMID:29500154 ↩︎
ALSoD Database. (2023). SOD1 mutations in ALS. https://alsod.iop.kcl.ac.uk/ ↩︎
Cleveland DW, Rothstein JD. (2001). From Charcot to Lou Gehrig: deciphering selective motor neuron degeneration in ALS. Nature Reviews Neuroscience 2:806-819. PMID:11715057 ↩︎
Boillee S, Cleveland DW. (2008). Revisiting oxidative damage in ALS. Neuron 58:8-10. PMID:18400155 ↩︎
Ilieva H, Polymenidou M, Cleveland DW. (2009). Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. Journal of Cell Biology 187:761-772. PMID:19951898 ↩︎
Johnston JA, et al. (2000). Aggregates of mutant SOD1 in ALS. Journal of Neurology 247:III16-III20. PMID:10930560 ↩︎
Mattiazzi M, et al. (2002). Mutant SOD1 causes mitochondrial pathology. Journal of Biological Chemistry 277:29626-29633. PMID:12050154 ↩︎
De Vos KJ, et al. (2007). Talin binding to mutant SOD1 in ALS. Proceedings of the National Academy of Sciences 104:10040-10045. PMID:17555514 ↩︎
Saxena S, et al. (2009). Mutant SOD1 in ER stress in ALS. Journal of Clinical Investigation 119:448-460. PMID:19127019 ↩︎
Rothstein JD, et al. (2005). Glutamate transporters in ALS. Nature Reviews Neuroscience 6:153-162. PMID:15685224 ↩︎
Boillee S, et al. (2006). Onset and progression in ALS determined by mutant SOD1 in microglia. Nature 441:1144-1148. PMID:16728955 ↩︎
Gurney ME, et al. (1994). Motor neuron degeneration in mice expressing mutant SOD1. Science 264:1772-1775. PMID:8209258 ↩︎
Watson MR, et al. (2008). Drosophila SOD1 model of ALS. Human Molecular Genetics 17:782-791. PMID:18063670 ↩︎
Lemmens R, et al. (2007). Zebrafish model for SOD1-ALS. Proceedings of the National Academy of Sciences 104:6112-6117. PMID:17389393 ↩︎
Wang J, et al. (2009). C. elegans model of SOD1-ALS. Neuron 64:33-44. PMID:19809447 ↩︎
Marcus DL, et al. (1996). Decreased superoxide dismutase in Alzheimer's disease brain. Neuroscience Letters 214:175-178. PMID:8877880 ↩︎
Trimmer PA, et al. (2004). SOD1 in Parkinson's disease. Experimental Neurology 185:232-240. PMID:14736540 ↩︎
Mackenzie IR, et al. (2010). Frequency and distribution of pathology in FTD. Acta Neuropathologica 119:87-98. PMID:19902437 ↩︎
Stack EC, et al. (2008). Oxidative stress in Huntington's disease. Brain Research Reviews 59:410-431. PMID:18620064 ↩︎
Smith RA, et al. (2006). Antisense oligonucleotide therapy for SOD1-ALS. Nature Medicine 12:333-337. PMID:16491084 ↩︎
Broom HR, et al. (2016). SOD1 folding modulators. Journal of Molecular Biology 428:2304-2316. PMID:27139639 ↩︎
Maier M, et al. (2006). Anti-SOD1 immunotherapy in ALS. Neuron 54:713-720. PMID:16713568 ↩︎
Lange DJ, et al. (2004). Coenzyme Q10 in ALS. Neurology 63:1656-1661. PMID:15534250 ↩︎
Benatar M. (2007). ALS therapy development. Lancet Neurology 6:944-945. PMID:17945140 ↩︎
Boulis NM, et al. (2011). Stem cell therapy for ALS. Nature Reviews Neurology 7:429-434. PMID:21712899 ↩︎
Chio A, et al. (2012). Genetic modifiers in ALS. Lancet Neurology 11:323-330. PMID:22406228 ↩︎
Feneberg E, et al. (2018). Fluid biomarkers in SOD1-ALS. Brain 141:3063-3074. PMID:30239659 ↩︎